Table 1.
Population information for the gestational diabetes mellitus (GDM) 2018 annual GDM screening cohort
| Test | All women, n = 4970 | European, n = 2468 (49.7%) | Māori, n = 1517 (30.5%) | Pacific, n = 187 (3.8%) | Asian, n = 660 (13.3%) | MELAA, n = 114 (2.3%) | Other, n = 24 (0.5%) |
|---|---|---|---|---|---|---|---|
| HbA1c measured, n (%) | 4581 (92.2) | 2322 (94.1) | 1365 (90.0) | 165 (88.2) | 602 (91.2) | 107 (93.9) | 20 (83.3) |
| <20 weeks | 4131 (83.1) | 2203 (89.3) | 1123 (74.0) | 130 (69.5) | 564 (85.5) | 92 (80.7) | 19 (79.2) |
| ≥20 weeks | 450 (9.1) | 119 (4.8) | 242 (16.0) | 35 (18.7) | 38 (5.8) | 15 (13.2) | 1 (4.2) |
| HbA1c with further screening, n (%) | 3609 (72.6) | 1898 (81.7) | 906 (59.7) | 131 (70.1) | 561 (85.0) | 96 (84.2) | 17 (70.8) |
| HbA1c and no further screening, n (%) | 972 (19.6) | 424 (19.2) | 459 (30.3) | 34 (18.2) | 41 (6.2) | 11 (9.6) | 3 (12.5) |
| Median gestation of HbA1c test, (IQR) | 6.2 (4.5, 10.5) | 5.6 (4.3, 8.4) | 8.4 (5.4, 15.0) | 9.7 (5.8, 17.4) | 5.7 (4.3, 8.3) | 6.6 (4.3, 13.1) | 5.9 (4.1, 10.4) |
| GCT or GTT screening (any time point), n (%) | 3832 (77.1) | 1989 (80.6) | 972 (64.1) | 142 (75.9) | 608 (92.1) | 101 (88.6) | 20 (83.3) |
| Initial GCT/GTT <24 weeks | 396 (8.0) | 182 (7.4) | 86 (5.7) | 10 (5.3) | 103 (15.6) | 9 (7.9) | 6 (25.0) |
| Initial GCT/GTT 24–28 weeks | 2290 (46.1) | 1289 (52.2) | 472 (31.1) | 70 (37.4) | 377 (57.1) | 72 (63.2) | 10 (14.7) |
| Initial GCT/GTT >28 weeks | 1146 (23.1) | 518 (21.0) | 414 (27.3) | 62 (33.2) | 128 (19.4) | 20 (17.5) | 4 (16.7) |
| Median gestation of initial GCT/GTT test (IQR) | 27.0 (25.4, 28.4) | 27.0 (25.5, 28.1) | 27.4 (25.7, 29.1) | 27.7 (26.1, 30.0) | 26.4 (24.6, 27.9) | 26.3 (24.9, 27.5) | 25.0 (23.3, 27.0) |
| Women screened as per Ministry of Health guideline, 14 n (%) | 2071 (41.7) | 1201 (48.7) | 410 (27.0) | 58 (31.0) | 331 (50.2) | 63 (55.3) | 8 (33.3) |
GCT, glucose challenge test; GTT, glucose tolerance test; IQR, interquartile range; MELAA, Middle Eastern/Latin American/African.